



Investor Presentation

Q4 FY 2024

May 2nd, 2024

Important Disclosure

Except for the historical information contained herein, statements in this presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continue', 'anticipate', 'estimate', 'intend', 'plan', 'contemplate', 'seek to', 'future', 'objective', 'goal', 'likely', 'project', 'on-course', 'should', 'potential', 'pipeline', 'guidance', 'will pursue' 'trend line' and similar expressions or variations of such expressions may constitute 'forward-looking statements'.

These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements.

These risks and uncertainties include, but are not limited to Ajanta Pharma's ability to successfully implement its strategy, the Company's growth and expansion plans, obtain regulatory approvals, provisioning policies, technological changes, investment and business income, cash flow projections, exposure to market risks as well as other risks.

Ajanta Pharma Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

These materials are not a prospectus, a statement in lieu of a prospectus, an offering circular, an invitation or an advertisement or an offer document under the Indian Companies Act, 2013 together with the rules and regulations made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, or any other applicable law in India. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States or in any other jurisdiction.

Contents



Ajanta at a Glance

Branded Generic Business

India, Asia, Africa – Diversified markets enables growth



2

US Generic Business

Selective play & normalized price erosion assists growth



Africa Institution Business

In-line performance

R&D & Manufacturing

6

5

Strong formulation capabilities



Financials

Improved margins



Strategy Initiatives

Levers for growth



Sustainability Initiatives


Committed to sustainable practices




Ajanta at a Glance



We are present in 30 countries globally



Branded Generics in India & EM is sizeable part of the business






4,800+ Medical Representatives globally for promotion of

products


2nd May 2024



Market diversification in Branded Generics enables continued growth



Our Business is well diversified & gives us an edge




Branded Generic Business






We have a strong brand franchise in India




Our leading brands continue to post healthy growth



Source: IQVIA MAT Mar 2024

11 ajanta

We continue to outperform industry growth



IPM = Indian Pharmaceutical Market, Source: IQVIA, MAT

IPM

Branded Generic Business



Growth continues



We have wide presence in markets & therapies



Key Markets

Africa, South East Asia, Middle East Asia & Central Asia


Leadership

In many molecules & sub-therapeutic segments


Among Top 10 Players in many markets



We were pioneers for front-end presence in EM



We are optimistic of consistent growth in EM






Generic Business

USA

Selective product portfolio; strong supply chain & robust quality compliance

Our US strategy of selective play pays




2nd May 2024


Institution Business





Our Institution business is of Anti-Malaria in Africa








R&D & Manufacturing

Strong Formulation Development Capabilities



Our R&D continues to provide product innovation





<u>Q4</u> FY 2024 - Rs. 50 cr. (Rs. 63 cr.) FY 2024 - Rs. 208 cr. (Rs. 237 cr.) 5% of Revenue

Strong Capabilities

- 800+ Scientists
- Formulation Development
- Analytical Development
- API Development
- Bio-Analytical Lab
- Drug Regulatory Affairs
- IPR

•

2nd May 2024

Our 7 plants are **best in class**



Paithan (Maharashtra)

Guwahati

(Assam)

Tablets, Capsules & Powder

Tablets, Capsules & Powder

Dahej (Gujarat)



Tablets, Capsules, Ointments & Sterile Eye Drops



Tablets & Capsules


Pithampur (Madhya Pradesh)

Financial Highlights

Higher margins



Branded Generics Sales Continues to Grow




ajanta


So also Total Sales continues to grow



ajanta

26





India takes the lead in Branded Generics Sales Consolidated 10% 11% 10% 5% India Asia **Africa Total** (Rs. cr.) (Rs. cr.) (Rs. cr.) (Rs. cr.) 1,0 2,94 1,30 57 957 9 585 8 1,17 559 2,690 4 ■FY23 ■FY24 ■FY23 ■FY24 ■FY23 ■FY24 FY23 FY24 26% 71% 31% 14% of Total Revenue of Total Revenue of Total Revenue of Total Revenue ajanta


2nd May 2024


Healthy overall growth



ajanta

28





31%

(Rs. cr.)

■FY23 ■FY24

6%

190

249

EBITDA @ 26% with consistent efforts



(INR Cr)	Q4 FY 2023	% to RO	Q4 FY 2024	% to RO	% Growth
Revenue from Operations (RO)	882		1,054		20%
COGS	(241)	27%	(264)	25%	
Gross Profit	641	73%	790	75%	23%
Employee Benefit	(224)	25%	(234)	22%	4%
Other Expenses	(268)	30%	(278)	26%	4%
EBITDA	149	17%	278	26%	86%
Depreciation	(33)	4%	(34)	3%	
Finance Cost	(1)	0%	(2)	0%	
Other Income	37	4%	36	3%	
Profit Before Tax	152	17%	278	26%	83%
Tax Expense	(30)	3%	75	7%	
Net Profit	122	14%	203	19%	66%
Other Comprehensive Income	(5)	1%	(7)	0%	
Total Comprehensive Income	117	13%	196	19%	67%





Profitability improves with cost optimization

(INR Cr)	FY 2023	% to RO	FY 2024	% to RO	% Growth
Revenue from Operations (RO)	3,743		4,209		12%
COGS	(1,051)	28%	(1,067)	25%	
Gross Profit	2,692	72%	3,142	75%	17%
Employee Benefit	(785)	21%	(900)	21%	15%
Other Expenses	(1,124)	31%	(1,070)	25%	(5%)
EBITDA	783	21%	1,172	28%	50%
Depreciation	(131)	3%	(135)	3%	
Finance Cost	(6)	0%	(7)	0%	
Other Income	99	3%	85	2%	
Profit Before Tax	745	20%	1,114	26%	49%
Tax Expense	(157)	4%	(298)	7%	
Net Profit	588	16%	816	19%	39%
Other Comprehensive Income	15	0%	1	0%	
Total Comprehensive Income	603	16%	817	19%	36%

Improving working capital efficiency



Rs. cr.

Statement of Assets & Liabilities	FY 2023		FY 2024	
ASSETS				
Non-Current Assets				
Property, Plant and Equipment	1,416		1,399	
Capital Work-in-Progress	209		256	
Right for use assets	81		80	
Other non-current assets	139		172	
Sub-total - Non-current assets	1,845	39%	1,907	41%
Current Assets				
Inventories	816	80 days	828	73 days
Trade Receivables	1,057	104 days	1,247	109 days
Bank Balance incld. Investments	841		461	
Other Current Assets	120		195	
Sub-total - Current Assets	2,834	61%	2,731	59%
Total - Assets	4,679		4,638	


Healthy retained earnings




Rs. cr.

Statement of Assets & Liabilities	FY 2023		FY 2024	
EQUITY AND LIABILITIES				
Equity				
Equity Share Capital	25		25	
Other Equity	3,363		3,542	
Sub Total – Shareholders' Funds	3,388	72%	3,567	77%
Non-current Liabilities				
Non-current Liabilities	152		175	
Sub Total – Non-Current Liab.	152	3%	175	4%
Current Liabilities				
Trade payables	423	79 days	463	85 days
Other current liabilities	716		433	
Sub Total – Current Liabilities	1,139	25%	896	19%
Total – Equity and Liabilities	4,679		4,638	

We have track record of consistent growth



Our ratios & cashflows are among best in industry





Note: 1. ROCE calculated as EBIT / (Net worth + Lease liability + Deferred tax liability)

2. ROE calculated as Net profit / Average net worth

3. Cash Conversion Ratio calculated as CFO (CashFlow from Operations) / EBITDA

So also Earnings & Pay Out






Book Value per share 283 264 252 FY22 FY23 FY24

• Bonus issue in April 2022 adjusted in all years for calculation of EPS & Book Value.

• Payout of 9M FY24 includes 2nd interim dividend declared but yet to be paid.

We continue to improve on working capital front



Strategy Initiatives

Levers for Growth



Our growth levers for continued growth



New products launches across markets

Strong product portfolio under registration and development in R&D

Increase market share in existing products Focus on field force productivity enhancement

Increasing the field presence as needed Adding field selectively in existing countries

Add new countries

Initiated work to enter selective new countries

Focus on digitalization & data analytics

Across all functions of the organization

Sustainability Initiatives



Sustainability: Committed to be responsible

Environment

Commissioned **8.8 MW** solar plant Hazardous waste put to use in cement plant

Quality First

Resource efficiency & low-carbon processes Highest quality products with no recalls

Zero Tolerance

for child labor, forced labor, sexual harassment & discrimination



Education, Healthcare & Rural Development for benefit of marginalized & vulnerable

Earning Call Details



Q4 FY24 Earnings Conference Call

Earnings Conference Call Dial-in Information

Date and Time	May 02, 2024 at		
	1630 – 1730 hrs IST		
	1900 – 2000 hrs SST/HKT		
	1200 – 1300 hrs BST		
	0700 – 0800 hrs US ET		
Dial-in Numbers			
Diamond pass link for faster access	Click <u>here</u> to register		
Universal Access	Primary Access: +91 22 6280 1542		
	+91 22 7115 8372		
International Toll	USA: 18667462133		
Free Number	UK: 08081011573		
	Hong Kong: 800964648		
	Singapore: 8001012045		

Thank you

For more information please visit our website: www.ajantapharma.com For regular updates follow us on twitter

www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal: 022-66061377 rajeev.agarwal@ajantapharma.com

Abhineet Kumar: 022-66061814 abhineet.kumar@ajantapharma.com

Ajanta House, Charkop, Kandivli (W), Mumbai 400 067 CIN No. - L24230MH1979PLC022059

